[Effect of irbesartan of the function of hemocoagulative component of hemostasis in patients with arterial hypertension during metabolic syndrome].
The aim of the study was to assess effects of irbesartan on disturbed platelet hemostasis in patients with arterial hypertension and metabolic syndrome. 38 patients received this drug for 16 weeks. Dynamics of lipid peroxidation in plasma and platelets, antioxidative protection of liquid blood fraction and platelets were estimated. The data were treated by the Student's t-test. Therapy with irbesartan for 4 months improved lipid peroxidation and primary hemostasis. Its continuation following the same regimen is expected to strengthen the obtained effect.